ACET
No price yet
Announcements
Nothing here yet
Daily updates
- Adicet Bio reported Phase 1 prula-cel data in systemic lupus erythematosus, showing a 54% DORIS remission rate and a 50% complete renal response at 12 months.Sep 29, 2026
- Adicet Bio reported Phase 1 prula-cel data in systemic lupus erythematosus with or without lupus nephritis, showing a 54% DORIS remission rate and a 50% complete renal response at 12 months.Sep 28, 2026
FDA designations
Nothing here yet
News
- Adicet Bio reports positive safety and efficacy data from the prula-cel (formerly ADI-001) study in systemic lupus erythematosus patients with or without lupus nephritisSep 28, 2026
- Adicet Bio received FDA clearance of its IND application for ADI-212Aug 28, 2026
- Adicet Bio announces first patient dosed in Phase 1 clinical trial of ADI-001 in treatment-refractory rheumatoid arthritis (RA)Oct 16, 2025
- Adicet Bio announces positive preliminary data from ADI-001 Phase 1 study in patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE)Oct 7, 2025
- Adicet Bio announces first systemic sclerosis patient dosed in ongoing Phase 1 clinical trial of ADI-001 in autoimmune diseasesJul 24, 2025